"Rhabdomyosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Descriptor ID |
D012208
|
| MeSH Number(s) |
C04.557.450.590.550.660 C04.557.450.795.550.660
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rhabdomyosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Rhabdomyosarcoma".
This graph shows the total number of publications written about "Rhabdomyosarcoma" by people in this website by year, and whether "Rhabdomyosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 4 | 2 | 6 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 5 | 0 | 5 |
| 2015 | 4 | 0 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 4 | 0 | 4 |
| 2018 | 3 | 0 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 5 | 0 | 5 |
| 2021 | 9 | 0 | 9 |
| 2022 | 10 | 0 | 10 |
| 2023 | 13 | 0 | 13 |
| 2024 | 13 | 0 | 13 |
| 2025 | 14 | 0 | 14 |
| 2026 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rhabdomyosarcoma" by people in Profiles.
-
The impact of genetic ancestry on survival outcomes in pediatric rhabdomyosarcoma: A report from the Children's Oncology Group. HGG Adv. 2025 Jul 10; 6(3):100466.
-
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers. JCO Precis Oncol. 2025 Feb; 9:e2400556.
-
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group. JAMA Netw Open. 2024 03 04; 7(3):e244170.
-
Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group. J Natl Cancer Inst. 2023 06 08; 115(6):733-741.
-
Pediatric rhabdomyosarcoma incidence and survival in the United States: An assessment of 5656 cases, 2001-2017. Cancer Med. 2023 02; 12(3):3644-3656.
-
Is Detection of Relapse by Surveillance Imaging Associated With Longer Survival in Patients With Rhabdomyosarcoma? J Pediatr Hematol Oncol. 2022 08 01; 44(6):305-312.
-
K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications. Dis Model Mech. 2022 02 01; 15(2).
-
Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2022 Jan 15; 128(2):317-325.
-
Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood. J Pathol. 2021 09; 255(1):52-61.
-
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019 11 05; 29(6):1675-1689.e9.